Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02886585 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab In Central Nervous System Metastases
A Phase 2 study of Brain Metastases, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
- 2
- Study locations
NCT02886585: Active Phase 2 study of Brain Metastases, sponsored by Massachusetts General Hospital.
NCT02886585 is a Phase 2 study of Brain Metastases that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 101 participants, below the 211-participant average among 67 other Brain Metastases trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02886585, a Phase 2 study of Brain Metastases, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
Primary Outcome
Contrast-enhanced cranial MRI will be performed every 6 weeks. Intracranial benefit rate is defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD) by RANO (Response assessment in neuro-oncology) criteria for brain metastases. CR is defined as the complete disappearance of all disease sustained for at least 4 weeks. PR is defined as greater than or equal to 30% decrease compared to baseline in the sum of target lesions sustained for at lea
Conditions Studied
Interventions
- DRUG Pembrolizumab
- PROCEDURE Stereotactic Radiosurgery
- RADIATION MRI
- RADIATION PET/CT
Study Locations (2)
Massachusetts
- Priscilla Brastianos - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2016-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What the registry record for NCT02886585 still lists
NCT02886585 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 211-participant average among 67 other Brain Metastases trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02886585 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02886585 about?
NCT02886585 is a clinical study titled "Pembrolizumab In Central Nervous System Metastases". This research study is studying Pembrolizumab as a possible treatment for this diagnosis for metastases in the central nervous system (brain and spinal cord).
What is the current status of trial NCT02886585?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2016-10. Estimated completion is 2027-12.
What conditions does trial NCT02886585 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT02886585?
The interventions under investigation include: Pembrolizumab (DRUG), Stereotactic Radiosurgery (PROCEDURE), MRI (RADIATION), PET/CT (RADIATION).
Who is sponsoring clinical trial NCT02886585?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02886585 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02886585's enrollment target sits among peer trials
101 14th of 67 higher than 54 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia